Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 142 clinical trials
Mobilization of Stem Cells With AMD3100 (Plerixafor) in Combination With G-CSF in Multiple Myeloma Patients

This is a single-group treatment, phase IV, open label study to assess the mobilization efficacy and safety of plerixafor in combination with G- CSF in male and female participants from 18 to 75 years of age with multiple myeloma for autologous transplantation. Study Duration-Screening-up to 30-day. Intervention and CD34+cells apheresis …

  • 0 views
  • 29 May, 2022
  • 1 location
Muscle Stimulation for Physical Function During Stem Cell Transplant

Some blood, bone marrow, and lymphatic (hematologic) cancers such as Hodgkin/Non-Hodgkin lymphomas, chronic lymphocytic leukemia, and multiple myeloma, are over-represented in Veterans due to exposures including Agent Orange and an increased percentage of patients of African American ethnicity. Hematologic transplantation (HCT) is a common treatment for these cancers, but often …

  • 0 views
  • 14 May, 2022
  • 1 location
Mobilization of Stem Cells With AMD3100 (Plerixafor) in Combination With G-CSF in Multiple Myeloma Patients

This is a single-group treatment, phase IV, open label study to assess the mobilization efficacy and safety of plerixafor in combination with G- CSF in male and female participants from 18 to 75 years of age with multiple myeloma for autologous transplantation. Study Duration-Screening-up to 30-day. Intervention and CD34+cells apheresis …

  • 0 views
  • 13 May, 2022
  • 1 location
BREntuximab Vedotin in SEcond LIne Therapy BEfore Transplant

Brentuximab Vedotin Consolidation (instead of Autologous Hematopoietic Stem Cell Transplantation) in Those who Attained a Metabolic Complete Remission after Salvage Therapy

  • 0 views
  • 27 Jan, 2021
  • 19 locations
GVD±R Regimen for ASCT-eligible Patients With Refractory/Relapsed DLBCL

rituximab) regimen for autologous hematopoietic stem cell transplantation(ASCT)-eligible patients with refractory/relapsed diffuse large B-cell lymphoma.

rituximab
doxorubicin
gemcitabine
b-cell lymphoma
cell transplantation
  • 13 views
  • 15 Feb, 2022
  • 1 location
Targeted Dose-Escalated Intravenous Busulfan and Bolus Etoposide as Preparative Therapy for Patients With Acute Myeloid Leukemia Undergoing Autologous Stem Cell Transplantation

The study hypothesis is that higher dose intravenous busulfan can be delivered safely to AML patients undergoing autologous transplantation. If this hypothesis is true the investigators plan to examine in a future study whether higher-dose busulfan can improve overall survival following autologous transplantation for AML.

cytarabine
busulfan
cell transplantation
ara-c
  • 20 views
  • 07 Nov, 2020
  • 1 location
Randomized Trial of Curcumin to Reduce Mucositis in Autologous Transplant Setting

reducing cytokine levels and the incidence and duration of mucositis in patients undergoing autologous stem cell transplantation.

  • 0 views
  • 30 May, 2021
  • 1 location
Chemotherapy and Imatinib in Young Adults With Acute Lymphoblastic Leukemia Ph (BCR-ABL) POSITIVE

histocompatible donor or contraindications for its realization it is recommended imatinib and chemotherapy, although there are studies that have undergone an autologous HSCT, followed or not treatment

  • 103 views
  • 26 Mar, 2022
  • 73 locations
CNCT19 Following ASCT in Patients With Relapsed or Refractory B-cell Lymphoma

The primary objective of this study is to explore the safety and efficacy of CNCT19 (a second-generation anti-CD19 CAR T-cell using 4-1BB as co-stimulatory domain provided by Juventas, Tianjin, China) infusion following ASCT in patients with relapsed or refractory B-cell lymphoma.

  • 0 views
  • 23 Mar, 2022
  • 1 location
Response-based Treatment of High-risk Neuroblastoma

The purpose of this study is to improve outcome of high risk neuroblastoma by tailoring the treatment intensity of tandem high dose chemotherapy according to the treatment response to induction chemotherapy.

  • 3 views
  • 21 Jan, 2021